Search Results - "Gras, Ashley"

A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern by Wayham, Nicholas P, Niedecken, Ariel R, Simons, Jan Fredrik, Chiang, Yao Y, Medina-Cucurella, Angélica V, Mizrahi, Rena A, Wagner, Ellen K, Gras, Ashley, Segal, Ilana, Witte, Peyton, Enstrom, Alexis, Bountouvas, Aristea, Nelson, Sabrina M, Weinberger, Tess, Tan, David, Asensio, Michael A, Subramanian, Alagu, Lim, Yoong Wearn, Adler, Adam S, Keating, Sheila M

“…Abstract Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from…”
Get full text

A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New SARS-CoV-2 Variants of Concern by Wayham, Nicholas P, Niedecken, Ariel R, Simons, Jan Fredrik, Chiang, Yao Y, Medina-Cucurella, Angélica V, Mizrahi, Rena A, Wagner, Ellen K, Gras, Ashley, Segal, Ilana, Witte, Peyton, Enstrom, Alexis, Bountouvas, Aristea, Nelson, Sabrina M, Weinberger, Tess, Tan, David, Asensio, Michael A, Subramanian, Alagu, Lim, Yoong Wearn, Adler, Adam S, Keating, Sheila M

“…Emerging variants of SARS-CoV-2 possess mutations that prevent antibody therapeutics from maintaining anti-viral binding and neutralizing efficacy. Monoclonal…”
Get full text

1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models by Stone, Erica, Carter, Kyle, Wagner, Ellen, Asensio, Michael, Benzie, Emily, Chiang, Yao, Coles, Garry, Edgar, Chelsea, Bishal Gautam, Gras, Ashley, Jackson, Leong, Leong, Renee, Manickam, Vishal, Mizrahi, Rena, Niedecken, Ariel, Saini, Jasmeen, Sandhu, Savreet, Simons, Jan Fredrick, Stadtmiller, Kacy, Tinsley, Brendan, LaRee Tracy, Wayham, Nicholas, Yoong Wearn Lim, Johnson, David, Adler, Adam

“…BackgroundAnti-CTLA-4 antibodies such as ipilimumab were among the first immuno-oncology agents to show significantly improved outcomes for patients. However,…”
Get full text